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Abstract
Background:  Studies have shown that metabolic syndrome and its consequent biochemical
derangements in the various phases of diabetes may contribute to carcinogenesis. A part of this
carcinogenic effect could be attributed to hyperinsulinism. High levels of insulin decrease the
production of IGF-1 binding proteins and hence increase levels of free IGF-1. It is well established
that bioactivity of free insulin growth factor 1 (IGF-1) increases tumor turnover rate. The objective
is to investigate the role of insulin resistance/sensitivity in carcinogenesis by studying the relation
between insulin resistance/sensitivity and IGF-1 levels in cancer patients. We postulate that
hyperinsulinaemia which prevails during initial phases of insulin resistance (condition prior to overt
diabetes) increases bioactivity of free IGF-1, which may contribute to process of carcinogenesis.
Methods/Design: Based on our pilot study results and power analysis of the same, we have
designed a two group case-control study. 800 proven untreated cancer patients (solid epithelial cell
tumors) under age of 50 shall be recruited with 200 healthy subjects serving as controls. Insulin
resistance/sensitivity and free IGF-1 levels shall be determined in all subjects. Association between
the two parameters shall be tested using suitable statistical methods.
Discussion: Well controlled studies in humans are essential to study the link between insulin
resistance, hyperinsulinaemia, IGF-1 and carcinogenesis. This study could provide insights to the
role of insulin, insulin resistance, IGF-1 in carcinogenesis although a precise role and the extent of
influence cannot be determined. In future, cancer prevention and treatment strategies could
revolve around insulin and insulin resistance.
Background
The association of diabetes mellitus and cancer has been
reported more than 100 years ago [1]. Population studies
have shown increased evidence of this association. Diabe-
tes has been recognized as a risk factor for development of
breast, endometrial, colorectal and pancreatic carcinomas
[2]. Breast, endometrial, colorectal and pancreatic carci-
nomas are best studied with regard to their association
with diabetes/insulin resistance. Population studies have
shown that the effects of diabetes mellitus on colorectal
cancer may be mediated through mechanisms ranging
from increased colonic transit time to hyperinsulinaemia.
In relation to the latter, at least in the early phase of devel-
opment, type 2 diabetes mellitus is associated with
increased circulating insulin concentrations [3,4]. A large
cohort study concluded that diabetes is associated with a
modestly increased risk for endometrial cancer among
women [5]. Future research, particularly prospective stud-
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ies with biological samples, could be very helpful in
answering questions aimed at clarifying these mecha-
nisms [5]. Data suggest that type 2 diabetes might be asso-
ciated with up to 10–20% excess risk for breast cancer and
that it could also have detrimental effects on the natural
history, diagnosis, and treatment of breast cancer [1,6].
In the past few years both laboratory investigations and
population studies have provided some circumstantial
evidence that insulin growth factor (IGF) physiology
influences cancer risk [7]. Insulin resistance is the under-
lying pathology of type 2 diabetes mellitus and is a com-
ponent of metabolic syndrome [8,9]. Over the years,
prospective studies have shown that metabolic syndrome
and its consequent biochemical derangements may con-
tribute to carcinogenesis. Several studies implicate hyper-
insulinism, a condition that prevails prior to the onset of
diabetes (part of metabolic syndrome) as candidate medi-
ator in carcinogenesis [10]. Studies have revealed that
high levels of circulating insulin decreases levels of insulin
like growth factor binding protein 1 and 3 (IGFBP 1,3).
Thus free IGF-1 levels increase in circulation [11,12].
Another aspect of IGF physiology is the IGF signaling. In
this signaling process, IGF-1 receptor is a predominant
factor and is crucial for tumor transformation and survival
of malignant cell. It has comparatively less role in normal
cell growth [13]. Thus role of IGF-1 in promoting carcino-
genesis and its prognosis is well established. Over the
recent years, IGF-1 physiology has been widely studied.
The IGF system, comprises of insulin-like IGF-I, IGF-II,
and IGFBPs. IGF-1 as a growth factor plays a dominant
role over IGF-2 and hence is widely studied. Until
recently, growth hormone was the only known stimulant
of IGF-1 production. Different lines of evidence suggest
that the IGF/IGFBP system may be regulated by factors
other than growth hormones. States of nutritional depri-
vation, such as starvation and protein caloric under-nutri-
tion and type 1 diabetes mellitus, in animal models have
long been known to influence the production of IGFs [14-
16]. Various studies have shown that resistance to insulin
action, as found in diabetic patients, has been associated
with an increase IGFBP-3 protease activity, there by reduc-
ing IGFBP-3 levels [17]. Also, Insulin increases IGF-I bio-
availability through IGFBP-1 suppression [14,18,19].
Thus there is ample evidence to suggest that insulin resist-
ant states increase free IGF-1 levels.
Medical literature suggests that well controlled biochemi-
cal and genetic studies are required to establish the link
between insulin, IGF-1, diabetes and cancer. We propose
to investigate the role of hyperinsulinemia in carcinogen-
esis.
The primary objective of the study is to investigate the role
of insulin resistance or sensitivity in carcinogenesis. This
is done by studying the relation between insulin resist-
ance/sensitivity and IGF-1 levels in cancer patients. The
secondary objective is to study the above mentioned asso-
ciation with organ specific cancers if possible.
Carcinogenesis is multi-factorial. The metabolic and
genetic derangements that take place during carcinogene-
sis may be induced by carcinogens and inherited genetic
factors. The role of either could be variable in a given case.
We hypothesize that people with insulin resistance are at
risk of developing cancer due to high levels of circulating
IGF-1. Such a risk would increase if other such factors are
prevalent/acquired. A person with high levels of IGF-1
may be predisposed to cancer and his/her risk of develop-
ing cancer would increase with the presence of other such
factors. Cancer being a non-communicable disease, with
multiple risk factors, modifiable risk factors are very few.
Controlling hyperinsulinaemia would modify one major
risk factor. IGF-1 levels in body change with age. In addi-
tion, risk factors for cancer and carcinogen exposure
increase with age [20]. Thus age and known carcinogens
could be major confounders.
In a pilot study conducted at our centre (unpublished
data) to test the above hypothesis we found a strong trend
towards significance in patients under the age of 50.
Genetic factors play a major role in carcinogenesis in
young patients (below 50 yrs). Hence IGF-1 and insulin
may play a larger role in patients below 50 years. Thus we
limit our study to cancer patients below the age of 50.
IGF-1 has high bioactivity on epithelial cells. Thus their
role in carcinomas is of significance rather than other
types of malignancies. Hence we limit our study to carci-
nomas of breast, GIT, liver, prostate, uterus, cervix and
ovaries.
Methods/Design
Structure of study
This is a two-group, prospective, case-control study. First
group shall comprise of newly diagnosed cancer patients,
for whom treatment has not been initiated. The second
group shall consist of subjects from normal population.
Fasting blood sugar (FBS) shall be estimated for all sub-
jects in both the groups. This is to rule out undiagnosed
diabetes mellitus. A FBS level above 126 mg% is diagnos-
tic of diabetes [21]. Fasting insulin level and IGF-1 level
will be assayed in the same blood sample for all subjects.
Sample size
Based on an unpublished pilot study results (conducted
on 63 patients) 761 patients and 191 controls are required
to expect a study power of 80 %. We plan to recruit 800
patients and 200 controls. Controls would be age and sex
matched to that of the patients.BMC Endocrine Disorders 2007, 7:10 http://www.biomedcentral.com/1472-6823/7/10
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Data and Sample collection
All subjects will be recruited from out patient division of
M.S. Ramaiah Memorial Hospital, Bangalore, India and
Cancer Institute, Chennai, India. Patients who are below
age of 50, with carcinomas of breast, GIT, liver, prostate,
uterus, ovaries and cervix shall be recruited. The exclusion
criteria are; patients who have undergone treatment for
cancer. Therapies for cancer including surgery and chem-
otherapy alter IGF-1 levels, growth factors and immune
mediators. Patients on palliative therapy due to very
advanced cancer and malnourished patients will also be
excluded as these patients will have low IGF-1 levels due
to cachexia [20]. Malnourishment will be assessed by Sub-
jective Global Assessment (SGA) method [22]. Patients
with endocrine related diseases, multiple endocrine neo-
plasia syndrome will also be excluded as IGF-1 is a sec-
ondary hormone and can be influenced by major
hormone imbalances. Patients with diabetes mellitus
(Type 1 and 2) will be excluded as such patients can have
low IGF-1 levels due to altered nourishment. Patients with
chronic liver diseases other than cancer will also be
excluded as liver is a major producer of IGF-1. All patients
with proven tobacco related cancers will be excluded.
Group 2 consists of subjects from normal population.
Subjects without any chronic or acute diseases will be con-
sidered. Subjects under treatment for any medical dis-
eases, subjects who are malnourished or subjects who
have family history of cancer or subjects who have body
mass index greater than 25 will be excluded. All the above
factors affect IFG-1 levels.
After obtaining an informed consent from subjects of
both groups, a detailed, relevant clinical history will be
documented. A 5 ml fasting venous blood sample (by
standard venous puncture) from all the recruited patients
will be drawn. Free IGF-1, fasting blood sugar and fasting
Insulin assays will be estimated on all samples.
Laboratory Assays
8 hour fasting plasma blood sugar will be done by glucose
oxidase – peroxidase (GOD-POD) method. Fasting insu-
lin will be assayed by (Radioimmunoassay) RIA method
using commercially available insulin RIA kit supplied by
Diagnostic Systems Laboratories Inc., Texas. IGF-1 will be
assayed by Immunoradiometric assay (IRMA) method
using a commercially available IRMA kit supplied by the
same company.
Analysis
Homeostasis model assessment-insulin resistance
(HOMA-IR) method will be used to calculate insulin
resistance/sensitivity [23]. The same will be associated
with IGF-1 levels using various statistical tools as men-
tioned below.
Data Management
All data elements recorded during the study period will be
entered and validated in Microsoft Excel. All variables and
changes will be transferred into the Satastical Package for
Social Sciences (SPSS), SYSTAT™ statistical software, sum-
marized (Counts, Minimum, Maximum, Mean, Median,
Standard Deviation) within each treatment group, trans-
ferred to the statistical report and then reformatted. Suita-
ble graphs will be generated to depict the changes in key
efficacy parameters and then transferred to the statistical
report.
Statistics
Descriptive Statistics
Descriptive statistics for each numerical variable will be
summarized as the frequency, percentage, mean, median
and standard deviations for all the subjects at each time
interval in each study group.
Statistical methods
Chi-square test and Fisher exact tests will be used to ana-
lyze the frequency data, Student't' test (two-tailed) will be
used to test the significance of study parameters between
case and controls. Analysis of variance/Kruskal Wallis test
will be used for within group analysis. Any other suitable
statistical techniques will be used to find the effect of
study parameters.
Control of Type -1 Error
All statistical tests will be conducted at the 0.05 alpha lev-
els, meaning that P ≤ 0.05 will be considered "nominally
significant". The Adjustment for multiple tests will be
done by applying Bonferroni correction to the p-values.
The p-value for the comparison of the primary efficacy
endpoints between Cases and Control group will be con-
sidered to be conclusive.
Software
The Statistical software namely SPSS 11.0 and Systat 8.0
will be used for the analysis of the data and Microsoft
word and Excel shall be used to generate graphs and
tables.
Sub-Group Analysis
A similar analysis will be carried out on organ-specific
cancers like breast, colon and rectum, depending on
number of patients recruited.
Ethical Issues
The study has been approved by Ethical Review Boards of
all centers involved in the study. (Approval Ref – MSRMC/
ERB/2007/06-01 dated 12th June 2007).BMC Endocrine Disorders 2007, 7:10 http://www.biomedcentral.com/1472-6823/7/10
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Informed Consent Process
The investigators shall provide to the subjects, all the
study related information in a language desired by the
subject and at a level of complexity that is understandable
to the subjects and the guardians. Prior to the subjects'
participation in the study, the written informed consent
form shall be signed and dated personally by the subject,
the guardian, the investigator and impartial witness.
Interim Analysis
Two interim analyses shall be carried out. First analysis
will be done once 30 % of patients are recruited. The sec-
ond analysis will be done once 60 % of them are recruited.
Recruitment will stop if the study attains positive signifi-
cance at end of interim analysis.
Discussion
Since carcinogenesis is multifactorial, various external car-
cinogens, genetic factors and metabolic derangements
contribute to carcinogenesis. Diabetes mellitus type 2 and
its associated metabolic derangements have been studied
for their role in development of cancer. Hyperinsulinae-
mia ensues in early phase of insulin resistance which is
responsible for variety of metabolic derangements. Hyper-
insulinaemia has also been implicated as a candidate
mediator in carcinogenesis [10].
High levels of insulin decrease binding proteins of IGF-1
[14,18,19]. IGF-1 signaling has been highly implicated in
development of cancers, especially epithelial cell cancers
(carcinomas). The IGF-1 signaling system plays a crucial
role in tumor transformation, malignant cell turn over
and survival of cancer cells. Such roles in normal cell
growth are comparatively less [13,24,25]. The insulin IGF-
1 system relationship and role of IGF-1 in carcinogenesis
have been independent lines of investigations. However,
well controlled studies in humans are essential to study
the link between insulin resistance, hyperinsulinaemia,
IGF-1 and carcinogenesis.
We hypothesize that hyperinsulinaemia which marks the
early phase of insulin resistance could decrease IGFBP
production. This results in increase in free IGF-1 in blood.
Thus, bioavailability of free IGF-1 increases, which could
mediate carcinogenesis in presence of other mediating
factors. Should this hypothesis test positive, then it would
be show insights to the role of insulin and insulin resist-
ance in carcinogenesis.
A pilot study on 63 subjects was conducted to test this
hypothesis (unpublished data). A trend towards signifi-
cance of association between insulin resistance/sensitivity
and IGF-1 levels was seen. The trend was stronger in
patients below the age of 50. Insulin resistance and asso-
ciated derangements are largely attributed to genetic fac-
tors [26,27]. Thus, advanced age could be a confounder
for this line of investigation. The study shall be conducted
on cancer patients, below the age of 50 years, with solid
tumors (carcinomas). The study also includes a control
group consisting of subjects from normal population. Var-
ious associations between IGF-1 and insulin resistance/
sensitivity shall be determined by suitable statistical
methods. However, the precise role of IGF-1 and the
extent of influence of IGF-1 system on carcinogenesis can-
not be determined in this study
This study could add to the knowledge and insights into
insulin's relationship with IGF-1 system and insulin's role
in carcinogenesis. The role of insulin and insulin resist-
ance would be an interesting subject in cancer prevention
and treatment.
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